Short Interest in Terumo Corp. (OTCMKTS:TRUMY) Drops By 91.6%

Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 30,823 shares, a drop of 91.6% from the April 15th total of 367,048 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 350,364 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

TRUMY has been the topic of a number of research analyst reports. Zacks Research raised Terumo to a “hold” rating in a report on Thursday, April 9th. Nomura raised shares of Terumo to a “hold” rating in a report on Tuesday, February 24th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Terumo has a consensus rating of “Hold”.

Get Terumo alerts:

Check Out Our Latest Stock Report on Terumo

Terumo Price Performance

OTCMKTS TRUMY traded up $0.13 during trading on Wednesday, hitting $12.28. 193,669 shares of the stock traded hands, compared to its average volume of 375,721. The company has a market capitalization of $18.11 billion, a P/E ratio of 21.16 and a beta of 0.62. The firm has a 50-day simple moving average of $13.10 and a 200-day simple moving average of $14.07. The company has a quick ratio of 0.89, a current ratio of 1.51 and a debt-to-equity ratio of 0.07. Terumo has a 12-month low of $12.08 and a 12-month high of $20.12.

Terumo (OTCMKTS:TRUMY – Get Free Report) last released its quarterly earnings data on Friday, February 13th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.82 billion. Terumo had a return on equity of 9.01% and a net margin of 11.74%. As a group, analysts predict that Terumo will post 0.58 EPS for the current year.

Terumo Company Profile

(Get Free Report)

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

See Also

• Five stocks we like better than Terumo
• Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
• Why OpenAI’s IPO Plans Could Be a Massive Win for Microsoft
• A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
• Ally Financial Is Back to Basics—And Investors Are Watching

Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.